Glycomine

Executive Summary

Glycomine is a clinical-stage biotechnology company pioneering substrate replacement therapies for serious rare genetic diseases. Its lead candidate, GLM101, is a mannose-1-phosphate replacement therapy currently in a Phase 2b trial for PMM2-CDG, the most common congenital disorder of glycosylation. PMM2-CDG is a devastating multisystem disease with no approved therapies, representing a significant unmet medical need. Glycomine’s approach aims to restore the deficient metabolite, potentially halting or reversing disease progression. The company has completed Phase 1/2 studies showing favorable safety and biomarker activity, positioning GLM101 as a potential first-in-class treatment. With a focused pipeline and a clear regulatory path, Glycomine is advancing toward pivotal data readouts. The Phase 2b trial is expected to enroll approximately 40 patients, with top-line results anticipated in the second half of 2026. Positive data would support registration and potentially accelerate time to market. The company’s strong scientific foundation and orphan drug designation in both the US and EU provide commercial incentives. However, execution risks remain, including enrollment challenges for a rare disease and the need for substantial capital to fund late-stage development. Overall, Glycomine represents a high-upside opportunity in the rare disease space, with a near-term catalyst that could significantly de-risk the investment thesis.

Upcoming Catalysts (preview)

• H2 2026Phase 2b Top-Line Data for GLM101 in PMM2-CDG60% success